Cargando…
The risk of PD-L1 expression misclassification in triple-negative breast cancer
PURPOSE: Stratification of patients with triple-negative breast cancer (TNBC) for anti-PD-L1 therapy is based on PD-L1 expression in tumor biopsies. This study sought to evaluate the risk of PD-L1 misclassification. METHODS: We conducted a high-resolution analysis on ten surgical specimens of TNBC....
Autores principales: | Ben Dori, Shani, Aizic, Asaf, Zubkov, Asia, Tsuriel, Shlomo, Sabo, Edmond, Hershkovitz, Dov |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239943/ https://www.ncbi.nlm.nih.gov/pubmed/35622241 http://dx.doi.org/10.1007/s10549-022-06630-3 |
Ejemplares similares
-
Automatic ganglion cell detection for improving the efficiency and accuracy of hirschprung disease diagnosis
por: Greenberg, Ariel, et al.
Publicado: (2021) -
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2021) -
Perineural invasion detection in pancreatic ductal adenocarcinoma using artificial intelligence
por: Borsekofsky, Sarah, et al.
Publicado: (2023) -
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
por: O’Shaughnessy, Joyce, et al.
Publicado: (2022) -
Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study
por: van Roozendaal, Lori M., et al.
Publicado: (2016)